Fluticasone furoate/vilanterol (Relvar™ Ellipta™)

Assessment Status Rapid Review Complete
Drug Fluticasone furoate/vilanterol
Brand Relvar™ Ellipta™
Indication For both (i) the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta-2-agonist. and (ii) for symptomatic treatment of patients with COPD with a FEV1<70% of predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.
Assessment Process
Rapid review commissioned 10/12/2013
Rapid review completed 23/12/2013
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.